Bisphosphonates in renal osteodystrophy.
The present review considers the role that bisphosphonates might have in patients with renal failure. Although bisphosphonates are widely used to reduce fracture risk in patients with osteoporosis, few studies have documented their effect in patients with renal osteodystrophy. The pathogenesis of bone loss after renal transplantation and the role of the recently identified osteoprotegerin/receptor activating nuclear factor-kappaB system is described. Inhibition of bone resorption may prove beneficial when high bone turnover is present, but there are potential drawbacks to widespread use of bisphosphonates. These issues are discussed, with emphasis placed on reports published within the past 18 months.
Fan
S L
SL
Department of Nephrology, St Bartholomew's and The Royal London Hospitals, London, UK. stanley.fan@virgin.net
Cunningham
J
J
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D017582:Renal Replacement Therapy / Q000009:adverse effects; D013329:Structure-Activity Relationship
D004164:Diphosphonates